Drug news
CHMP recommends Tivicay for HIV- Viiv Healthcare
The European Medicines Agency�s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Tivicay (dolutegravir) from ViiV HealthCare in combination with other antiretroviral medicines for the treatment of adults and adolescents over 12 years of age infected with Human Immunodeficiency Virus (HIV).
Tivicay can be used in adult patients with and without resistance to the integrase class and in adolescents infected with HIV-1 without resistance to the integrase class.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.